Euroasian Journal of Hepato-Gastroenterology

Register      Login

VOLUME 9 , ISSUE 2 ( July-December, 2019 ) > List of Articles

Original Article

Treatment by Transarterial Chemoembolization and Sorafenib for Hepatocellular Carcinoma vs Advanced Hepatocellular Carcinoma in Bangladesh: A Real-life Situation

Md Abdur Rahim, Sheikh Mohammad Noor-E-Alam, Mohammad Ashraful Alam, Faiz Ahmad Khondaker, Ahmed Lutful Moben, Jhumur Ghosh, Md Sakirul Islam Khan

Keywords : Hepatocellular carcinoma, Sorafenib, Transarterial chemoembolization

Citation Information : Rahim MA, Noor-E-Alam SM, Alam MA, Khondaker FA, Moben AL, Ghosh J, Khan MS. Treatment by Transarterial Chemoembolization and Sorafenib for Hepatocellular Carcinoma vs Advanced Hepatocellular Carcinoma in Bangladesh: A Real-life Situation. Euroasian J Hepatogastroenterol 2019; 9 (2):63-66.

DOI: 10.5005/jp-journals-10018-1300

License: CC BY-NC 4.0

Published Online: 01-12-2019

Copyright Statement:  Copyright © 2019; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Background: Although there are thousands of patients with hepatocellular carcinoma (HCC) in Bangladesh, almost there is no nationwide recommendations for therapeutic maneuver for HCC patients. As most of the HCC patients of Bangladesh are diagnosed late, patients with advanced HCC with large and multiple HCC nodules represent the usual presentation of HCC. The study is presented here to assess the effects of a combined therapy of transarterial chemoembolization (TACE) and sorafenib in advanced HCC patients. Materials and methods: A total of 77 patients with advanced HCC were enrolled in this study. All of them had advanced HCC with variable etiologies and clinical conditions. All patients were treated by TACE and also given systemic sorafenib at the same time. The patients were checked 1 and 3 months after therapy commencement. Results: Out of 77 patients, 18 patients died within 1 month and additional 15 patients died within 3 months after therapy commencement. Thus, there remains 44 surviving patients after 3 months. When different parameters of dead patients and survived patients were compared, no specific parameters dictated the factors about overall survival of more than 3 months. Discussion: This is the first approach to initiate an invasive and a systemic therapy for treatment of advanced HCC in Bangladesh. Further follow-up of patients and their long-term overall survival may cast some lights about the role of these therapies in Bangladeshi HCC patients.


PDF Share
  1. Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 2019;16(10):589–604. DOI: 10.1038/s41575-019-0186-y.
  2. Rawla P, Sunkara T, Muralidharan P, et al. Update in global trends and aetiology of hepatocellular carcinoma. Contemp Oncol (Pozn) 2018;22(3):141–150. DOI: 10.5114/wo.2018.78941.
  3. Noor-E-Alam SM. Management of hepatocellular carcinoma: Bangladesh perspective. Euroasian J Hepatogastroenterol 2018;8(1):52–53. DOI: 10.5005/jp-journals-10018-1258.
  4. Cahill BA, Braccia D. Current treatment for hepatocellular carcinoma. Clin J Oncol Nurs 2004;8(4):393–399. DOI: 10.1188/04.CJON.393-399.
  5. Wege H, Li J, Ittrich H. Treatment lines in hepatocellular carcinoma. Visc Med 2019;35(4):266–272. DOI: 10.1159/000501749.
  6. Kew MC. Hepatocellular carcinoma in developing countries: prevention, diagnosis and treatment. World J Hepatol 2012;4(3): 99–104. DOI: 10.4254/wjh.v4.i3.99.
  7. Mahtab MA, Chaudhury M, Uddin MH, et al. Cost assessment of hepatitis B virus-related hepatitis in Bangladesh. Euroasian J Hepatogastroenterol 2016;6(2):163–166. DOI: 10.5005/jp-journals-10018-1190.
  8. Chen QF, Wu PH, Huang T, et al. Efficacy of treatment regimens for advanced hepatocellular carcinoma: a network meta-analysis of randomized controlled trials. Medicine (Baltimore) 2019;98(40):e17460. DOI: 10.1097/MD.0000000000017460.
  9. Paul SB, Dhamija E, Gamanagatti SR, et al. Evaluation of tumor response to intra-arterial chemoembolization of hepatocellular carcinoma: comparison of contrast-enhanced ultrasound with multiphase computed tomography. Diagn Interv Imaging 2017;98(3):253–260. DOI: 10.1016/j.diii.2016.09.002.
  10. Agarwal A, Yadav AK, Kumar A, et al. Transarterial chemoembolization in unresectable hepatocellular carcinoma—assessing the factors affecting the survival: an audit from a tertiary care center in northern India. Indian J Gastroenterol 2015;34(2):117–126. DOI: 10.1007/s12664-015-0544-9.
  11. Goel M, Gaikwad V, Dharia T, et al. Preresection transarterial chemoembolization for hepatocellular carcinoma: an experience with 23 patients. Indian J Gastroenterol 2014;33(5):432. DOI: 10.1007/s12664-014-0490-y.
  12. Kudo M, Izumi N, Sakamoto M, et al. Survival analysis over 28 years of 173,378 patients with hepatocellular carcinoma in Japan. Liver Cancer 2016;5(3):190–197. DOI: 10.1159/000367775.
  13. Golabi P, Fazel S, Otgonsuren M, et al. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine 2017;96(9):e5904. DOI: 10.1097/MD.0000000000005904.
  14. Li L, Zhao W, Wang M, et al. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis. BMC Gastroenterol 2018;18(1):138. DOI: 10.1186/s12876-018-0849-0.
  15. Colagrande S, Inghilesi AL, Aburas S, et al. Challenges of advanced hepatocellular carcinoma. World J Gastroenterol 2016;22(34): 7645–7659. DOI: 10.3748/wjg.v22.i34.7645.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.